journal article·2025-10Open access

Natural Caffeic Acid‐Based Polyphenol‐Form Polymer as Self‐Therapeutic Drug Carrier Uniquely Targeting and Sensitizing Chemotherapy of Triple‐Negative Breast Cancer

Lezong Chen, Chunlei Dai, Liying Wang, Xinru You, Jun Wu, Yuanbin Song, Jingbo Xu

Small Structures· Volume 6· Issue 10

Abstract

Drug carriers constructed from natural plant‐derived bioactive molecules, such as polyphenols, not only provide a new strategy to enhance the drug therapy efficacy but also help bring sustainability concept to pharmaceutical industry. Here, the natural caffeic acid into polyphenol‐form polymer with free pendant phenolic hydroxyl groups (Ph‐CaA‐OH) is prepared by one step, simple, and mild polycondensation method, then it is utilized as a self‐therapeutic drug carrier against triple‐negative breast cancer (TNBC). The Ph‐CaA‐OH can self‐assemble into sub‐100 nm nanoparticles (PCOH NPs) and exhibit unique dose‐dependent cytotoxicity to TNBC cell lines, promoting intracellular reactive oxygen species production and causing DNA double‐strand break damage. Moreover, PCOH NPs regulate the expression of Vimentin, ZEB‐1, and E‐cadherin to inhibit the epithelial‐mesenchymal transition progression of TNBC cells. The experimental results in vivo indicates that PCOH NPs could highly penetrate and accumulate inside the tumor, and both PCOH NPs and paclitaxel‐loaded PCOH NPs show stronger tumor suppressive effects than paclitaxel and Abraxane without significant side effects. This newly developed Ph‐CaA‐OH works excellent as a therapeutic nanodelivery platform with specific self‐anti‐TNBC activity and TNBC targeting capability, providing a new strategy for therapy of TNBC and other tumors, plus expanding the applications of polymerized caffeic acid‐based biomaterials.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Curcumin's Biomedical Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Hematologic Oncology Sun Yat‐sen University Cancer Center State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Guangzhou 510060 China

Department of Anesthesiology General Hospital of Southern Theatre Command of PLA Guangzhou 510010 China

Center for Nanomedicine and Department of Anesthesiology Brigham and Women's Hospital Harvard Medical School Boston 02115 USA

Bioscience and Biomedical Engineering Thrust The Hong Kong University of Science and Technology (Guangzhou) Guangzhou 511400 China

Division of Life Science The Hong Kong University of Science and Technology Hong Kong SAR China

Department of Hematology The Fifth Affiliated Hospital Sun Yat‐sen University Zhuhai 519000 China

Funding

National Natural Science Foundation of China

References (49)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.3390/cells809095710.3390/cells8090957 ↗
3. 10.1038/s41572-019-0111-210.1038/s41572-019-0111-2 ↗
4. 10.1016/j.cpt.2023.06.00210.1016/j.cpt.2023.06.002 ↗
5. 10.1038/s41467-022-31579-810.1038/s41467-022-31579-8 ↗
6. 10.1007/s12274-022-5002-210.1007/s12274-022-5002-2 ↗
7. 10.1016/j.medj.2022.12.00110.1016/j.medj.2022.12.001 ↗
8. Tao Y. · Chin. Chem. Lett. · 2023 · 35 · 10970
9. 10.1002/adma.20110014010.1002/adma.201100140 ↗
10. 10.1016/j.addr.2021.11400610.1016/j.addr.2021.114006 ↗
11. 10.1016/j.addr.2013.11.00910.1016/j.addr.2013.11.009 ↗
12. 10.1016/j.cclet.2023.10875210.1016/j.cclet.2023.108752 ↗
13. 10.1016/j.mattod.2022.11.00710.1016/j.mattod.2022.11.007 ↗
14. 10.1039/D4SC07198K10.1039/D4SC07198K ↗
15. 10.1002/smll.20190686110.1002/smll.201906861 ↗
16. 10.1016/j.copbio.2023.10301310.1016/j.copbio.2023.103013 ↗
17. 10.1021/acs.nanolett.1c0289910.1021/acs.nanolett.1c02899 ↗
18. 10.1002/adma.20210743410.1002/adma.202107434 ↗
19. 10.1002/adfm.20210080510.1002/adfm.202100805 ↗
20. 10.1016/j.cclet.2022.10782710.1016/j.cclet.2022.107827 ↗
21. 10.1360/SSC-2024-020910.1360/SSC-2024-0209 ↗
22. 10.1002/adma.20200349210.1002/adma.202003492 ↗
23. 10.1002/anie.20131113610.1002/anie.201311136 ↗
24. 10.1021/acs.nanolett.0c0502810.1021/acs.nanolett.0c05028 ↗
25. 10.1002/adfm.20180864610.1002/adfm.201808646 ↗
26. 10.1002/anie.20231450110.1002/anie.202314501 ↗
27. 10.1186/s12906-017-1984-910.1186/s12906-017-1984-9 ↗
28. 10.1016/0006-2952(94)90291-710.1016/0006-2952(94)90291-7 ↗
29. 10.1016/j.ijpharm.2010.09.03510.1016/j.ijpharm.2010.09.035 ↗
30. 10.1016/j.jfda.2016.05.00310.1016/j.jfda.2016.05.003 ↗
31. 10.1016/S0300-483X(02)00198-110.1016/S0300-483X(02)00198-1 ↗
32. 10.3390/nano706014810.3390/nano7060148 ↗
33. 10.1021/acs.jafc.6b0093110.1021/acs.jafc.6b00931 ↗
34. 10.1016/j.foodchem.2018.04.05510.1016/j.foodchem.2018.04.055 ↗
35. 10.1002/adma.20200735610.1002/adma.202007356 ↗
36. 10.1016/j.cmet.2015.06.00610.1016/j.cmet.2015.06.006 ↗
37. 10.1016/j.redox.2013.12.01110.1016/j.redox.2013.12.011 ↗
38. 10.1016/j.tem.2009.04.00110.1016/j.tem.2009.04.001 ↗
39. 10.1016/j.mrrev.2013.02.00110.1016/j.mrrev.2013.02.001 ↗
40. 10.1016/j.semcancer.2021.04.00110.1016/j.semcancer.2021.04.001 ↗
41. 10.1038/nrc349510.1038/nrc3495 ↗
42. 10.1039/C5MT00149H10.1039/C5MT00149H ↗
43. 10.2217/nnm-2021-037410.2217/nnm-2021-0374 ↗
44. 10.2174/138161282266616120814550810.2174/1381612822666161208145508 ↗
45. 10.3389/fphar.2022.84587110.3389/fphar.2022.845871 ↗
46. 10.1038/s41419-021-04114-810.1038/s41419-021-04114-8 ↗
47. 10.3389/fonc.2019.0132310.3389/fonc.2019.01323 ↗
48. 10.1158/0008-5472.CAN-07-293810.1158/0008-5472.CAN-07-2938 ↗
49. 10.3390/cells1006150410.3390/cells10061504 ↗